Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis

Gastroenterology

Volumn 144, Issue 5, 2013, Pages 1024-1030

  Hoshida, Yujin ^a   Villanueva, Augusto ^b   Sangiovanni, Angelo ^c   Sole, Manel ^b   Hur, Chin ^d   Andersson, Karin L ^d   Chung, Raymond T ^d   Gould, Joshua ^e   Kojima, Kensuke ^a   Gupta, Supriya ^e   Taylor, Bradley ^e   Crenshaw, Andrew ^e   Gabriel, Stacey ^e   Minguez, Beatriz ^a   Iavarone, Massimo ^c   Friedman, Scott L ^a   Colombo, Massimo ^c   Llovet, Josep M ^a,b,f   Golub, Todd R ^e,g,h  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c UNIVERSITY OF MILAN   (Italy)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^f INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^g BOSTON CHILDREN S HOSPITAL   (United States)

^h HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Early Detection; Liver Cancer Prevention; Screening; Whole Genome Gene Expression Profiling

Indexed keywords

FORMALDEHYDE;

ADULT; ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DEATH; DISEASE COURSE; DISEASE SURVEILLANCE; FEMALE; FOLLOW UP; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; ITALY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME;

EID: 84876474584     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2013.01.021     Document Type: Article

References (38)

1. D. Schuppan, N.H. Afdhal Liver cirrhosis Lancet 371 2008 838 851
2. S.L. Friedman Evolving challenges in hepatic fibrosis Nat Rev Gastroenterol Hepatol 7 2010 425 436
3. K.N. Ly, J. Xing, R.M. Klevens The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007 Ann Intern Med 156 2012 271 278
4. J.M. Llovet, A. Burroughs, J. Bruix Hepatocellular carcinoma Lancet 362 2003 1907 1917
5. M. Sherman Recurrence of hepatocellular carcinoma N Engl J Med 359 2008 2045 2047
6. J.M. Llovet, J. Bruix Novel advancements in the management of hepatocellular carcinoma in 2008 J Hepatol 48 Suppl 1 2008 S20 S37
7. K.L. Andersson, J.A. Salomon, S.J. Goldie Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis Clin Gastroenterol Hepatol 6 2008 1418 1424
8. Y. Popov, D. Schuppan Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies Hepatology 50 2009 1294 1306
9. Y. Hoshida, B.C. Fuchs, K.K. Tanabe Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges Curr Cancer Drug Targets 12 2012 1129 1159
10. A.S. Lok, J.E. Everhart, E.C. Wright Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C Gastroenterology 140 2011 840 849 quiz e12
11. A.M. Di Bisceglie, A.M. Stoddard, J.L. Dienstag Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon Hepatology 53 2011 1100 1108
12. R.N. Pugh, I.M. Murray-Lyon, J.L. Dawson Transection of the oesophagus for bleeding oesophageal varices Br J Surg 60 1973 646 649
13. P.S. Kamath, W.R. Kim The model for end-stage liver disease (MELD) Hepatology 45 2007 797 805
14. J.O. Smith, R.K. Sterling Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C Aliment Pharmacol Ther 30 2009 557 576
15. Y. Hoshida, A. Villanueva, M. Kobayashi Gene expression in fixed tissues and outcome in hepatocellular carcinoma N Engl J Med 359 2008 1995 2004
16. M. Colombo, R. de Franchis, E. Del Ninno Hepatocellular carcinoma in Italian patients with cirrhosis N Engl J Med 325 1991 675 680
17. A. Sangiovanni, E. Del Ninno, P. Fasani Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance Gastroenterology 126 2004 1005 1014
18. M. Vigano, A. Aghemo, M.A. Iavarone Increased survival of patients with HCV-related cirrhosis with a long-term response to interferon therapy (abstr) Hepatology 42 2005 432A
19. R.M. Simon, S. Paik, D.F. Hayes Use of archived specimens in evaluation of prognostic and predictive biomarkers J Natl Cancer Inst 101 2009 1446 1452
20. C. April, B. Klotzle, T. Royce Whole-genome gene expression profiling of formalin-fixed, paraffin-embedded tissue samples PLoS One 4 2009 e8162
21. Y. Hoshida Nearest template prediction: a single-sample-based flexible class prediction with confidence assessment PLoS One 5 2010 e15543
22. M. Reich, T. Liefeld, J. Gould GenePattern 2.0 Nat Genet 38 2006 500 501
23. M. Marcolongo, B. Young, F. Dal Pero A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C Hepatology 50 2009 1038 1044
24. G. D'Amico, G. Garcia-Tsao, L. Pagliaro Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies J Hepatol 44 2006 217 231
25. T. Luedde, R.F. Schwabe NF-kappaB in the liver-linking injury, fibrosis and hepatocellular carcinoma Nat Rev Gastroenterol Hepatol 8 2011 108 118
26. D.Y. Zhang, S.L. Friedman Fibrosis-dependent mechanisms of hepatocarcinogenesis Hepatology 56 2012 769 775
27. B.K. Abu Dayyeh, M. Yang, B.C. Fuchs A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma Gastroenterology 141 2011 141 149
28. K.K. Tanabe, A. Lemoine, D.M. Finkelstein Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis JAMA 299 2008 53 60
29. B.C. Fuchs, Y. Hoshida, T. Fujii EGFR inhibition prevents cirrhosis and hepatocellular carcinoma (abstr) Hepatology 54 2011 1222A
30. R. Simon The use of genomics in clinical trial design Clin Cancer Res 14 2008 5984 5993
31. J.M. Llovet, A.M. Di Bisceglie, J. Bruix Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 2008 698 711
32. R.S. Sandler, J.E. Everhart, M. Donowitz The burden of selected digestive diseases in the United States Gastroenterology 122 2002 1500 1511
33. S.F. Altekruse, K.A. McGlynn, M.E. Reichman Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005 J Clin Oncol 27 2009 1485 1491
34. G.L. Davis, M.J. Alter, H. El-Serag Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression Gastroenterology 138 2010 513 521 521 e1-6
35. A.P. Venook, C. Papandreou, J. Furuse The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective Oncologist 15 Suppl 4 2010 5 13
36. J.A. Davila, R.O. Morgan, P.A. Richardson Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States Hepatology 52 2010 132 141
37. M. Colombo Screening and diagnosis of hepatocellular carcinoma Liver Int 29 Suppl 1 2009 143 147
38. J. Bruix, M. Sherman Management of hepatocellular carcinoma: an update Hepatology 53 2011 1020 1022